Hangzhou ImmuQuad(艾沐蒽) Biotech, LLC.

Hangzhou ImmuQuad Biotech, LLC is a biotechnology company specializing in immune-driven medicine to alter the diagnosis and treatment of diseases. Founded in 2016 by Tao Sun and a scientific research team from the University of Chicago, the company is headquartered in Hangzhou, China. Sun serves as the CEO of the company.

The core of ImmuQuad's business is its proprietary immune medicine platform, which decodes the genetic information of the adaptive immune system. This platform is applied to the diagnosis, monitoring, and treatment of immune-mediated diseases, including cancer, autoimmune disorders, and infectious diseases. The company utilizes high-throughput sequencing of T-cell receptors (TCR) and B-cell receptors (BCR) to provide its services. Its main product lines include the ImmuHub® platform for TCR/BCR sequencing, Seq-MRD® for detecting minimal residual disease in leukemia and lymphoma, T-Classifier® for early disease screening using AI, and Immun-Cheq® for digital immunity assessment. The company also offers solutions for CAR-T therapy development and monitoring.

ImmuQuad's business model revolves around providing next-generation sequencing services and data analysis to researchers and clinicians. For instance, the company provides researchers with grants to use its ImmuHub® sequencing services. The firm has received funding from investors such as Bangshi Capital, Genetron Health, and Ruichuang Bio.

Keywords: immune-driven medicine, biotechnology, adaptive immune system, high-throughput sequencing, TCR sequencing, BCR sequencing, cancer diagnosis, autoimmune disease treatment, infectious disease, minimal residual disease, CAR-T, immunotherapy, immune repertoire, immune monitoring, liquid biopsy, precision medicine, molecular diagnostics, bioinformatics, next-generation sequencing, immunoinformatics